Targeting the recruitment of monocytes and macrophages in renal disease

Seminars in Nephrology

Volumn 30, Issue 3, 2010, Pages 318-333

  Vielhauer, Volker ^a   Kulkarni, Onkar ^a   Reichel, Christoph A ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antagonist; Chemokine; Chemokine receptor; Inflammation; Kidney; Macrophages

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; AMG 487; BIMOSIAMOSE; CCX 140; CCX 354; CELL ADHESION MOLECULE ANTAGONIST; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CHEMOKINE RECEPTOR CCR4 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR1 ANTAGONIST; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DPC 168; INCB 8696; INTEGRIN; INTEGRIN ANTAGONIST; KW 0761; MARAVIROC; MNL 1202; MNL 3897; SCH 527123; SELECTIN; SELECTIN ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DRUG TARGETING; GLOMERULONEPHRITIS; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; MACROPHAGE; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MONOCYTE; NEPHRITIS; NEPHROSCLEROSIS; PRIORITY JOURNAL; TISSUE REMODELING; WOUND HEALING;

ANIMALS; CHEMOKINES; CYTOKINES; DENDRITIC CELLS; FORECASTING; HUMANS; INTEGRINS; KIDNEY DISEASES; MACROPHAGES; MOLECULAR TARGETED THERAPY; MONOCYTES; SELECTINS;

EID: 77953885701     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.03.006     Document Type: Article

References (120)

1. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
2. Serbina N.V., Pamer E.G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006, 7:311-317.
3. Kulkarni O., Pawar R.D., Purschke W., Eulberg D., Selve N., Buchner K., et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007, 18:2350-2358.
4. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
5. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964.
6. Soos T.J., Sims T.N., Barisoni L., Lin K., Littman D.R., Dustin M.L., et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006, 70:591-596.
7. Ricardo S.D., van Goor H., Eddy A.A. Macrophage diversity in renal injury and repair. J Clin Invest 2008, 118:3522-3530.
8. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7:678-689.
9. Muller W.A. Mechanisms of transendothelial migration of leukocytes. Circ Res 2009, 105:223-230.
10. Ley K. Arrest chemokines. Microcirculation 2003, 10:289-295.
11. Ancuta P., Rao R., Moses A., Mehle A., Shaw S.K., Luscinskas F.W., et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003, 197:1701-1707.
12. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666-670.
13. Shaw S.K., Bamba P.S., Perkins B.N., Luscinskas F.W. Real-time imaging of vascular endothelial-cadherin during leukocyte transmigration across endothelium. J Immunol 2001, 167:2323-2330.
14. Martin-Padura I., Lostaglio S., Schneemann M., Williams L., Romano M., Fruscella P., et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998, 142:117-127.
15. Weber C., Fraemohs L., Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007, 7:467-477.
16. Schenkel A.R., Mamdouh Z., Chen X., Liebman R.M., Muller W.A. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002, 3:143-150.
17. Muller W.A., Weigl S.A., Deng X., Phillips D.M. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993, 178:449-460.
18. Shang X.Z., Issekutz A.C. Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol 1998, 28:1970-1979.
19. Bardin N., Blot-Chabaud M., Despoix N., Kebir A., Harhouri K., Arsanto J.P., et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2009, 29:746-753.
20. Wang S., Voisin M.B., Larbi K.Y., Dangerfield J., Scheiermann C., Tran M., et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J Exp Med 2006, 203:1519-1532.
21. Reichel C.A., Rehberg M., Bihari P., Moser C.M., Linder S., Khandoga A., et al. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling. J Leukoc Biol 2008, 83:864-874.
22. Voisin M.B., Woodfin A., Nourshargh S. Monocytes and neutrophils exhibit both distinct and common mechanisms in penetrating the vascular basement membrane in vivo. Arterioscler Thromb Vasc Biol 2009, 29:1193-1199.
23. Reichel C.A., Khandoga A., Anders H.J., Schlöndorff D., Luckow B., Krombach F. Chemokine receptors Ccr1, Ccr2, and Ccr5 mediate neutrophil migration to postischemic tissue. J Leukoc Biol 2006, 79:114-122.
24. Reichel C.A., Rehberg M., Lerchenberger M., Berberich N., Bihari P., Khandoga A.G., et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol 2009, 29:1787-1793.
25. Soehnlein O., Zernecke A., Eriksson E.E., Rothfuchs A.G., Pham C.T., Herwald H., et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood 2008, 112:1461-1471.
26. Pruenster M., Mudde L., Bombosi P., Dimitrova S., Zsak M., Middleton J., et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009, 10:101-108.
27. Tipping P.G., Huang X.R., Berndt M.C., Holdsworth S.R. P-selectin directs T lymphocyte-mediated injury in delayed-type hypersensitivity responses: studies in glomerulonephritis and cutaneous delayed-type hypersensitivity. Eur J Immunol 1996, 26:454-460.
28. Ogawa D., Shikata K., Matsuda M., Okada S., Wada J., Yamaguchi S., et al. Preventive effect of sulphated colominic acid on P-selectin-dependent infiltration of macrophages in experimentally induced crescentic glomerulonephritis. Clin Exp Immunol 2002, 129:43-53.
29. Rosenkranz A.R., Mendrick D.L., Cotran R.S., Mayadas T.N. P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. J Clin Invest 1999, 103:649-659.
30. Mulligan M.S., Johnson K.J., Todd R.F., Issekutz T.B., Miyasaka M., Tamatani T., et al. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest 1993, 91:577-587.
31. Takada M., Nadeau K.C., Shaw G.D., Marquette K.A., Tilney N.L. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997, 99:2682-2690.
32. Takada M., Nadeau K.C., Shaw G.D., Tilney N.L. Prevention of late renal changes after initial ischemia/reperfusion injury by blocking early selectin binding. Transplantation 1997, 64:1520-1525.
33. Lange-Sperandio B., Cachat F., Thornhill B.A., Chevalier R.L. Selectins mediate macrophage infiltration in obstructive nephropathy in newborn mice. Kidney Int 2002, 61:516-524.
34. Shikata K., Suzuki Y., Wada J., Hirata K., Matsuda M., Kawashima H., et al. L-selectin and its ligands mediate infiltration of mononuclear cells into kidney interstitium after ureteric obstruction. J Pathol 1999, 188:93-99.
35. Naruse T., Yuzawa Y., Akahori T., Mizuno M., Maruyama S., Kannagi R., et al. P-selectin-dependent macrophage migration into the tubulointerstitium in unilateral ureteral obstruction. Kidney Int 2002, 62:94-105.
36. Langer R., Wang M., Stepkowski S.M., Hancock W.W., Han R., Li P., et al. Selectin inhibitor bimosiamose prolongs survival of kidney allografts by reduction in intragraft production of cytokines and chemokines. J Am Soc Nephrol 2004, 15:2893-2901.
37. Kusaka M., Zandi-Nejad K., Kato S., Beato F., Nagano H., Shaw G.D., et al. Exploitation of the continuum between early ischemia/reperfusion injury and host alloresponsiveness: indefinite kidney allograft survival by treatment with a soluble P-selectin ligand and low-dose cyclosporine in combination. Transplantation 1999, 67:1255-1261.
38. Segerer S., Schlöndorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 2007, 27:260-274.
39. Sean Eardley K., Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005, 68:437-455.
40. Weber C., Weber K.S., Klier C., Gu S., Wank R., Horuk R., et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 2001, 97:1144-1146.
41. Tang W.W., Qi M., Warren J.S. Monocyte chemoattractant protein 1 mediates glomerular macrophage infiltration in anti-GBM Ab GN. Kidney Int 1996, 50:665-671.
42. Zernecke A., Weber K.S., Erwig L.P., Kluth D.C., Schroppel B., Rees A.J., et al. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 2001, 166:5755-5762.
43. Wada T., Yokoyama H., Furuichi K., Kobayashi K.I., Harada K., Naruto M., et al. Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 1996, 10:1418-1425.
44. Fujinaka H., Yamamoto T., Takeya M., Feng L., Kawasaki K., Yaoita E., et al. Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 1997, 8:1174-1178.
45. Panzer U., Thaiss F., Zahner G., Barth P., Reszka M., Reinking R.R., et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int 2001, 59:1762-1769.
46. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185:1371-1380.
47. Wenzel U., Schneider A., Valente A.J., Abboud H.E., Thaiss F., Helmchen U.M., et al. Monocyte chemoattractant protein-1 mediates monocyte/macrophage influx in anti-thymocyte antibody-induced glomerulonephritis. Kidney Int 1997, 51:770-776.
48. Li P., Garcia G.E., Xia Y., Wu W., Gersch C., Park P.W., et al. Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearance. Am J Pathol 2005, 167:637-649.
49. Keepers T.R., Gross L.K., Obrig T.G. Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome. Infect Immun 2007, 75:1229-1236.
50. Furuichi K., Wada T., Iwata Y., Kitagawa K., Kobayashi K., Hashimoto H., et al. Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 2003, 14:1066-1071.
51. Shimizu H., Maruyama S., Yuzawa Y., Kato T., Miki Y., Suzuki S., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003, 14:1496-1505.
52. Wada T., Furuichi K., Sakai N., Iwata Y., Kitagawa K., Ishida Y., et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004, 15:940-948.
53. Shimizu S., Nakashima H., Masutani K., Inoue Y., Miyake K., Akahoshi M., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 2004, 43:1121-1128.
54. Shimizu S., Nakashima H., Karube K., Ohshima K., Egashira K. Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin Exp Rheumatol 2005, 23:239-242.
55. Kanamori H., Matsubara T., Mima A., Sumi E., Nagai K., Takahashi T., et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007, 360:772-777.
56. Hasegawa H., Kohno M., Sasaki M., Inoue A., Ito M.R., Terada M., et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48:2555-2566.
57. Wu H., Wang Y., Tay Y.C., Zheng G., Zhang C., Alexander S.I., et al. DNA vaccination with naked DNA encoding MCP-1 and RANTES protects against renal injury in adriamycin nephropathy. Kidney Int 2005, 67:2178-2186.
58. Zheng G., Wang Y., Xiang S.H., Tay Y.C., Wu H., Watson D., et al. DNA vaccination with CCL2 DNA modified by the addition of an adjuvant epitope protects against "nonimmune" toxic renal injury. J Am Soc Nephrol 2006, 17:465-474.
59. Kulkarni O., Eulberg D., Selve N., Zollner S., Allam R., Pawar R.D., et al. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther 2009, 328:371-377.
60. Ninichuk V., Khandoga A.G., Segerer S., Loetscher P., Schlapbach A., Revesz L., et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007, 170:1267-1276.
61. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999, 190:1813-1824.
62. Tesch G.H., Schwarting A., Kinoshita K., Lan H.Y., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999, 103:73-80.
63. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
64. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
65. Furuichi K., Wada T., Iwata Y., Kitagawa K., Kobayashi K., Hashimoto H., et al. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol 2003, 14:2503-2515.
66. Li L., Huang L., Sung S.S., Vergis A.L., Rosin D.L., Rose C.E., et al. The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008, 74:1526-1537.
67. Kitagawa K., Wada T., Furuichi K., Hashimoto H., Ishiwata Y., Asano M., et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004, 165:237-246.
68. Pérez de Lema G., Maier H., Franz T.J., Escribese M., Chilla S., Segerer S., et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005, 16:3592-3601.
69. Bird J.E., Giancarli M.R., Kurihara T., Kowala M.C., Valentine M.T., Gitlitz P.H., et al. Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice. Kidney Int 2000, 57:129-136.
70. Moore K.J., Wada T., Barbee S.D., Kelley V.R. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Fas(1pr) mice. Kidney Int 1998, 53:1631-1641.
71. Panzer U., Schneider A., Wilken J., Thompson D.A., Kent S.B., Stahl R.A. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int 1999, 56:2107-2115.
72. Anders H.J., Frink M., Linde Y., Banas B., Wörnle M., Cohen C.D., et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003, 170:5658-5666.
73. Gröne H.J., Weber C., Weber K.S., Grone E.F., Rabelink T., Klier C.M., et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999, 13:1371-1383.
74. Song E., Zou H., Yao Y., Proudfoot A., Antus B., Liu S., et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002, 61:676-685.
75. Turner J.E., Paust H.J., Steinmetz O.M., Peters A., Meyer-Schwesinger C., Heymann F., et al. CCR5 deficiency aggravates crescentic glomerulonephritis in mice. J Immunol 2008, 181:6546-6556.
76. Topham P.S., Csizmadia V., Soler D., Hines D., Gerard C.J., Salant D.J., et al. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 1999, 104:1549-1557.
77. Anders H.J., Vielhauer V., Frink M., Linde Y., Cohen C.D., Blattner S.M., et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002, 109:251-259.
78. Anders H.J., Belemezova E., Eis V., Segerer S., Vielhauer V., Pérez de Lema G., et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004, 15:1504-1513.
79. Vielhauer V., Berning E., Eis V., Kretzler M., Segerer S., Strutz F., et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004, 66:2264-2278.
80. Ninichuk V., Gross O., Reichel C., Khandoga A., Pawar R.D., Ciubar R., et al. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol 2005, 16:977-985.
81. Bedke J., Kiss E., Schaefer L., Behnes C.L., Bonrouhi M., Gretz N., et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007, 7:527-537.
82. Furuichi K., Gao J.L., Horuk R., Wada T., Kaneko S., Murphy P.M. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury. J Immunol 2008, 181:8670-8676.
83. Eis V., Luckow B., Vielhauer V., Siveke J.T., Linde Y., Segerer S., et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004, 15:337-347.
84. Feng L., Chen S., Garcia G.E., Xia Y., Siani M.A., Botti P., et al. Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int 1999, 56:612-620.
85. Inoue A., Hasegawa H., Kohno M., Ito M.R., Terada M., Imai T., et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005, 52:1522-1533.
86. Oh D.J., Dursun B., He Z., Lu L., Hoke T.S., Ljubanovic D., et al. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008, 294:F264-F271.
87. Furuichi K., Gao J.L., Murphy P.M. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006, 169:372-387.
88. Chen S., Bacon K.B., Li L., Garcia G.E., Xia Y., Lo D., et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998, 188:193-198.
89. Garcia G.E., Xia Y., Harrison J., Wilson C.B., Johnson R.J., Bacon K.B., et al. Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am J Pathol 2003, 162:1061-1073.
90. Zarbock A., Schmolke M., Bockhorn S.G., Scharte M., Buschmann K., Ley K., et al. The Duffy antigen receptor for chemokines in acute renal failure: a facilitator of renal chemokine presentation. Crit Care Med 2007, 35:2156-2163.
91. Vielhauer V., Allam R., Lindenmeyer M.T., Cohen C.D., Draganovici D., Mandelbaum J., et al. Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines. Am J Pathol 2009, 175:119-131.
92. Nishikawa K., Guo Y.J., Miyasaka M., Tamatani T., Collins A.B., Sy M.S., et al. Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis. J Exp Med 1993, 177:667-677.
93. Kawasaki K., Yaoita E., Yamamoto T., Tamatani T., Miyasaka M., Kihara I. Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J Immunol 1993, 150:1074-1083.
94. Ghielli M., Verstrepen W.A., De Greef K.E., Helbert M.H., Ysebaert D.K., Nouwen E.J., et al. Antibodies to both ICAM-1 and LFA-1 do not protect the kidney against toxic (HgCl2) injury. Kidney Int 2000, 58:1121-1134.
95. Haller H., Dragun D., Miethke A., Park J.K., Weis A., Lippoldt A., et al. Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996, 50:473-480.
96. Dragun D., Tullius S.G., Park J.K., Maasch C., Lukitsch I., Lippoldt A., et al. ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. Kidney Int 1998, 54:590-602.
97. Cheng Q.L., Chen X.M., Li F., Lin H.L., Ye Y.Z., Fu B. Effects of ICAM-1 antisense oligonucleotide on the tubulointerstitium in mice with unilateral ureteral obstruction. Kidney Int 2000, 57:183-190.
98. Lange-Sperandio B., Schimpgen K., Rodenbeck B., Chavakis T., Bierhaus A., Nawroth P., et al. Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int 2006, 69:81-88.
99. Miyatake N., Shikata K., Sugimoto H., Kushiro M., Shikata Y., Ogawa S., et al. Intercellular adhesion molecule 1 mediates mononuclear cell infiltration into rat glomeruli after renal ablation. Nephron 1998, 79:91-98.
100. Sugimoto H., Shikata K., Hirata K., Akiyama K., Matsuda M., Kushiro M., et al. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997, 46:2075-2081.
101. Okada S., Shikata K., Matsuda M., Ogawa D., Usui H., Kido Y., et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 2003, 52:2586-2593.
102. Haberstroh U., Pocock J., Gomez-Guerrero C., Helmchen U., Hamann A., Gutierrez-Ramos J.C., et al. Expression of the chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int 2002, 62:1264-1276.
103. Janssen U., Ostendorf T., Gaertner S., Eitner F., Hedrich H.J., Assmann K.J., et al. Improved survival and amelioration of nephrotoxic nephritis in intercellular adhesion molecule-1 knockout mice. J Am Soc Nephrol 1998, 9:1805-1814.
104. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Tesch G.H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 2005, 16:1711-1722.
105. Wu X., Pippin J., Lefkowith J.B. Attenuation of immune-mediated glomerulonephritis with an anti-CD11b monoclonal antibody. Am J Physiol 1993, 264:F715-F721.
106. Wu X., Tiwari A.K., Issekutz T.B., Lefkowith J.B. Differing roles of CD18 and VLA-4 in leukocyte migration/activation during anti-GBM nephritis. Kidney Int 1996, 50:462-472.
107. Allen A.R., McHale J., Smith J., Cook H.T., Karkar A., Haskard D.O., et al. Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury. J Immunol 1999, 162:5519-5527.
108. Khan S.B., Allen A.R., Bhangal G., Smith J., Lobb R.R., Cook H.T., et al. Blocking VLA-4 prevents progression of experimental crescentic glomerulonephritis. Nephron 2003, 95:e100-e110.
109. Bedke J., Kiss E., Behnes C.L., Popovic Z.V., Heuser M., Stojanovic T., et al. Anti-inflammatory effects of alphav integrin antagonism in acute kidney allograft rejection. Am J Pathol 2007, 171:1127-1139.
110. Lenda D.M., Kikawada E., Stanley E.R., Kelley V.R. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol 2003, 170:3254-3262.
111. Lenda D.M., Stanley E.R., Kelley V.R. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice. J Immunol 2004, 173:4744-4754.
112. Le Meur Y., Tesch G.H., Hill P.A., Mu W., Foti R., Nikolic-Paterson D.J., et al. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leukoc Biol 2002, 72:530-537.
113. Jose M.D., Le Meur Y., Atkins R.C., Chadban S.J. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am J Transplant 2003, 3:294-300.
114. Lim A.K., Ma F.Y., Nikolic-Paterson D.J., Thomas M.C., Hurst L.A., Tesch G.H. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009, 52:1669-1679.
115. Ma F.Y., Liu J., Kitching A.R., Manthey C.L., Nikolic-Paterson D.J. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am J Physiol Renal Physiol 2009, 296:F177-F185.
116. Yu X.Q., Nikolic-Paterson D.J., Mu W., Giachelli C.M., Atkins R.C., Johnson R.J., et al. A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 1998, 110:50-64.
117. Okada H., Moriwaki K., Kalluri R., Takenaka T., Imai H., Ban S., et al. Osteopontin expressed by renal tubular epithelium mediates interstitial monocyte infiltration in rats. Am J Physiol Renal Physiol 2000, 278:F110-F121.
118. Ophascharoensuk V., Giachelli C.M., Gordon K., Hughes J., Pichler R., Brown P., et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999, 56:571-580.
119. Yoo K.H., Thornhill B.A., Forbes M.S., Coleman C.M., Marcinko E.S., Liaw L., et al. Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int 2006, 70:1735-1741.
120. Clauss S., Gross O., Kulkarni O., Avila-Ferrufino A., Radomska E., Segerer S., et al. Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy. J Pathol 2009, 218:40-47.